Skip Navigation

European Heart Journal 2001 22(23):2148-2163; doi:10.1053/euhj.2001.3036
Copyright © 2001 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Review Article

New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias

Members of the Sicilian Gambitf1

Received June 29, 2001; accepted September 19, 2001

Abstract

Cardiac arrhythmias complicate many diseases affecting the heart and the circulation, and incorporate a multiplicity of underlying mechanisms. The evolution of scientific knowledge has made the complex changes produced by cardiovascular disease sufficiently understood at the organ, cellular, and molecular levels such that there is a diversity of therapeutic targets for pharmacological therapy and/or prevention. Moreover, the approach of rational drug design, in mechanism- and disease-specific fashion, facilitates targeting of therapy via molecular, structural and translational biology. Additional approaches, employing similar drug-design strategies but based on gene therapy and transcriptional and translational modification are on the horizon. Hence, there is reason to be optimistic regarding the design, testing and clinical availability of novel antiarrhythmic therapies.

Key Words: Molecular biology, gene therapy, genes, electrophysiology, pharmacology

f1 Correspondence: Michael R. Rosen, MD, Gustavus A. Pfeiffer Professor of Pharmacology, Professor of Pediatrics, Director, Center for Molecular Therapeutics, College of Physicians & Surgeons of Columbia University, Department of Pharmacology, 630 West 168 Street, PH7W-321, New York, NY 10032, U.S.A.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Am Coll CardiolHome page
M. V. Podgoreanu and D. A. Schwinn
New Paradigms in Cardiovascular Medicine: Emerging Technologies and Practices: Perioperative Genomics
J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1965 - 1977.
[Abstract] [Full Text] [PDF]

Home page
 HeartHome page
T. Kahan and L. Bergfeldt
Left ventricular hypertrophy in hypertension: its arrhythmogenic potential
Heart, February 1, 2005; 91(2): 250 - 256.
[Full Text] [PDF]

Home page
 CirculationHome page
M. R. Rosen
The Electrocardiogram 100 Years Later: Electrical Insights Into Molecular Messages
Circulation, October 22, 2002; 106(17): 2173 - 2179.
[Full Text] [PDF]

Home page
 CirculationHome page
A. H. Madrid, M. G. Bueno, J. M.G. Rebollo, I. Marin, G. Pena, E. Bernal, A. Rodriguez, L. Cano, J. M. Cano, P. Cabeza, et al.
Use of Irbesartan to Maintain Sinus Rhythm in Patients With Long-Lasting Persistent Atrial Fibrillation: A Prospective and Randomized Study
Circulation, July 16, 2002; 106(3): 331 - 336.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.